Our ALKtALK replay on Empowering Wellness w/ Dr Narjust Florez, MD, FASCO is now available.

We discuss the big issues across our community. In this snippet, Dr Florez shares the industry discussion on finding effective doses over maximum tolerated ones.

📺youtu.be/fxtLVrfAUrQ?si… #LCSM

Healthcare marketing seems to be realising that you can’t trawl your way through blogs and the internet to understand the “patient experience.”

Seems the notion of talking to people with the lived experience is still novel - via The Drum

thedrum.com/opinion/2024/0…

Ilissa’s story highlights why we need more research. We need to do better than two year survival for people like Ilissa,taken too soon with the rarer BRAF-V600E #lungcancer mutation.

Thank you Young Lung Cancer Initiative 🤍

#MoreResearchMoreLife #MoreResearchLessCancer #lcsm

The ongoing development of Nuvalent’s zidesamtinib (NVL-520) is an important step forward for our ROS-1 #lungcancer & #cancer community. Here Dr Stephen V Liu, MD highlights the great promise & limited low grade toxicities.

onclive.com/view/dr-liu-on…

#lcsm ROS1ders UK The ROS1ders, Inc.

Exciting news from #ASCO24 ! Join the ultimate face-off between Paolo Tarantino and Aakash Desai, MD, MPH as we review the latest in breast 🦸‍♀️ and thoracic 🫁 oncology! Expect insights, debates, and a lot of fun!

Aakash Desai, MD, MPH: What are the 5 key #lcsm abstracts coming at #ASCO24 ? 🧵

Interesting analysis of mutagenic forces shaping #lungcancer in never-smokers (LCINS) from nearly 900 individuals #LCSM

We had an an amazing ALKtALK with the one and only Dr Narjust Florez, MD, FASCO. We spanned all the vital topics - from weight gain, relationships, sexual health & more.

We'll be sharing our replay shortly. Here's a behind the scenes shot with our co-hosts Summer, Yvonne & Dana. #LCSM

Tune into tonight at 6pm ET for our next ALKtALK with Dr Narjust Florez, MD, FASCO

Many of us with ALK+ cancer grapple with various issues - from side effects, family, palliative care and more. Come join us as we discuss everything around empowering wellness.

👉 alkpositive.org/alktalk

🚨🔥OncoAlert Hot off the Press.

New #Guidelines by ASCO & @IntegrativeOnc on:

“Management of #Cancer -related #Fatigue during & after cancer treatment.”

#Fatigue is a very common & distressing symptom in #Patients with #Cancer .
We CAN HELP them.

👇🏼
brnw.ch/21wJRao

We are becoming a FORCE! Read the full blog post at YLCI substack here: open.substack.com/pub/younglungc…

Why do some lung cancer patients have shorter responses to TKIs? - Oncogene Cancer Research
CU Anschutz Medical Campus

#Cancer #CU #MedicalCampus #LungCancer #OncoDaily #Oncogene #Cancer Research #Oncology

oncodaily.com/64821.html

Looking for get involved in #Cancersupport advocacy? We're speaking about lung cancer but convo applicable to all. Join us for this live and lively discussion of advocacy across continents. IASLC ASCO, thnx Yvonne Diaz for hosting.

Great video summary of #ADC landscape in #lungcancer . I share these concerns, though another niche for ADCs may be IN COMBO with TKIs for acquired resistance (eg, osi+MET ADC, osi+HER2/HER3 ADCs, etc). EGFR Resisters #LCSM Chat

Amongst the enthusiasm for Tarlatamab approval, let’s please pause to remember the pts with SCLC who were the true pioneers. Their time, devotion, + belief in the hope of research made this advance possible 🙏 LiveLung LUNGevity Foundation GO2 for Lung Cancer IASLC #LCSM Jill Feldman

Christine Lovly, MD, PhD LiveLung LUNGevity Foundation GO2 for Lung Cancer IASLC Jill Feldman Thank you for recognising the patients behind this. Advocacy is a team sport. Always grateful for our #lungcancer community - all dedicated researchers and clinicians who push science forward. Happy for our SCLC community and all

Fantastic news for our ALK+ #lungcancer community 🙌

The U.S. FDA has granted breakthrough therapy designation to Nuvalent's NVL-655 for the treatment of patients with locally advanced or metastatic ALK+ LC who have been previously treated 2+ TKIs.

#LCSM #ResearchSavesLives

In this age of #PrecisionMedicine , shouldn't drugs be funded according to #biomarker vs tumour origin?

Elaine Lynch's #lungcancer is HER2+, associated w #breastcancer . Her family is self-funding Enhertu bc not indicated for lung & can't keep up
👉metro.co.uk/2024/05/13/nev… #lcsm

New study for #EGFR + #LungCancer patients: Delaying treatments like PD-(L)1 inhibitors until biomarker results are in can reduce severe side effects like lung inflammation. Personalised treatments enhance safety and improve outcomes! #LCSM Clinical Lung Cancer

clinical-lung-cancer.com/article/S1525-…

Targeting EGFR and MET pathways to overcome resistance to targeted therapies. Thanks to the Hamoui Foundation, Lungevity, Dr. Patil and partners for this exciting research-- potentially relevant for multiple drivers!

lungevity.org/blogs/kicking-…

😱 Missed #BTOG24 ?
😳Forgot something from that excellent talk you went to?
😎Want to impress your MDT with your cutting edge knowledge?

✅ You can access the whole meeting from BTOG website (if you are a member)

✅Slides + video seamlessly available